Ruxolitinib

Ruxolitinib
Clinical data
Trade namesJakafi, Jakavi, Opzelura
Other namesINCB018424, INC424
AHFS/Drugs.comMonograph
MedlinePlusa612006
License data
Pregnancy
category
Routes of
administration		By mouth, topical
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability95%[10]
Protein binding97%[10]
MetabolismLiver (mainly CYP3A4-mediated)[10]
Elimination half-life2.8-3 hours[10]
ExcretionUrine (74%), faeces (22%)[10]
Identifiers
  • (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
PDB ligand
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H18N6
Molar mass306.373 g·mol−1
3D model (JSmol)
  • N#CCC(C1CCCC1)n1cc(-c2ncnc3[nH]ccc23)cn1
  • InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1 checkY
  • Key:HFNKQEVNSGCOJV-OAHLLOKOSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Ruxolitinib, sold under the brand name Jakafi among others, is a medication used for the treatment of intermediate or high-risk myelofibrosis,[6] a type of myeloproliferative neoplasm that affects the bone marrow;[11][12] polycythemia vera, when there has been an inadequate response to or intolerance of hydroxyurea;[6][13] and steroid-refractory acute graft-versus-host disease.[6] Ruxolitinib is a Janus kinase inhibitor.[6] It was developed and marketed by Incyte Corp in the US under the brand name Jakafi,[6] and by Novartis elsewhere in the world, under the brand name Jakavi.[14]

It was approved for medical use in the United States in 2011,[15] and in the European Union in 2012.[8] Ruxolitinib is the first FDA-approved pharmacologic treatment to address repigmentation in vitiligo patients.[16]

The crystal structure of ruxolitinib and of its dihydrate form are known.[17]

  1. ^ a b "JAKAVI (Novartis Pharmaceuticals Australia Pty LTD) | Therapeutic Goods Administration (TGA)". Archived from the original on 8 March 2023. Retrieved 8 March 2023.
  2. ^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
  3. ^ "JAKAVI ruxolitinib (as phosphate) 5 mg tablet blister pack (198934)". Therapeutic Goods Administration (TGA). 27 May 2022. Archived from the original on 8 March 2023. Retrieved 12 July 2024.
  4. ^ "Jakavi Product information". Health Canada. 22 October 2009. Archived from the original on 8 March 2023. Retrieved 7 March 2023.
  5. ^ "Jakavi 10mg Tablets - Summary of Product Characteristics (SmPC)". (emc). 5 April 2022. Archived from the original on 8 March 2023. Retrieved 7 March 2023.
  6. ^ a b c d e f "Jakafi- ruxolitinib tablet". DailyMed. 26 February 2020. Archived from the original on 3 November 2020. Retrieved 16 November 2020.
  7. ^ "Opzelura- ruxolitinib cream". DailyMed. Archived from the original on 1 November 2021. Retrieved 31 October 2021.
  8. ^ a b Cite error: The named reference Jakavi EPAR was invoked but never defined (see the help page).
  9. ^ "Opzelura EPAR". European Medicines Agency. 20 April 2023. Archived from the original on 24 April 2023. Retrieved 23 April 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  10. ^ a b c d e "Jakafi (ruxolitinib) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 12 December 2018. Retrieved 16 February 2014.
  11. ^ Mesa RA, Yasothan U, Kirkpatrick P (February 2012). "Ruxolitinib". Nature Reviews. Drug Discovery. 11 (2): 103–4. doi:10.1038/nrd3652. PMID 22293561. S2CID 233195859.
  12. ^ Harrison C, Mesa R, Ross D, Mead A, Keohane C, Gotlib J, et al. (October 2013). "Practical management of patients with myelofibrosis receiving ruxolitinib". Expert Review of Hematology. 6 (5): 511–23. doi:10.1586/17474086.2013.827413. PMC 8201600. PMID 24083419. S2CID 5470231.
  13. ^ Vannucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. (January 2015). "Ruxolitinib versus standard therapy for the treatment of polycythemia vera". The New England Journal of Medicine. 372 (5): 426–35. doi:10.1056/NEJMoa1409002. PMC 4358820. PMID 25629741.
  14. ^ "FDA Approves Jakafi® (Ruxolitinib) for the Treatment of Patients with Uncontrolled Polycythemia Vera". 4 December 2014. Archived from the original on 8 March 2023. Retrieved 8 March 2023.
  15. ^ Cite error: The named reference Drug Approval Package: Jakafi was invoked but never defined (see the help page).
  16. ^ "FDA approves topical treatment". U.S. Food and Drug Administration (FDA) (Press release). 19 July 2022. Archived from the original on 20 December 2022. Retrieved 20 December 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  17. ^ Peng Z, Ye L (August 2024). "Comparison of the crystal structures of the JAK1/2 inhibitor ruxolitinib and its hydrate and phosphate". Acta Crystallographica Section C. 80 (Pt 8): 440–447. Bibcode:2024AcCrC..80..440P. doi:10.1107/S2053229624006740. PMID 39046815.